CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Summary

The purpose of this study is to evaluate the efficacy of treatment with CPX-351 (an FDA approved drug for the treatment of AML) in individuals with MDS while using a new stratification tool to predict outcomes of participants following HMA failure. This approach is intended to gain a better understanding and insight into identifying new opportunities for drug approvals in this setting.

Timeline

Start

2019-07-25

Primary completion

2022-12-20

Completion

2022-12-20

Drugs

Indications